Microparticles and cardiotoxicity secondary to doxorubicin-based chemotherapy in breast cancer patients

Rodrigo M C Pestana; Andréa Teixeira-Carvalho; Luara I Dos Santos; Angélica N de Oliveira; Cintia E Soares; Adriano de P Sabino; Ricardo Simões; Karina B Gomes

doi:10.1016/j.ijcard.2023.131435

Microparticles and cardiotoxicity secondary to doxorubicin-based chemotherapy in breast cancer patients

Int J Cardiol. 2024 Jan 15:395:131435. doi: 10.1016/j.ijcard.2023.131435. Epub 2023 Oct 16.

Authors

Rodrigo M C Pestana¹, Andréa Teixeira-Carvalho², Luara I Dos Santos², Angélica N de Oliveira³, Cintia E Soares⁴, Adriano de P Sabino⁵, Ricardo Simões⁶, Karina B Gomes⁷

Affiliations

¹ Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Departamento de Ciências Fisiológicas, Universidade Federal do Maranhão, São Luís, Maranhão, Brazil.
² Fundação Oswaldo Cruz (Fiocruz), Instituto René Rachou, Belo Horizonte, MG, Brazil.
³ Instituto de Hipertensão, Belo Horizonte, Minas Gerais, Brazil.
⁴ Fundação Hospitalar do Estado de Minas Gerais (FHEMIG), Belo Horizonte, Minas Gerais, Brazil.
⁵ Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
⁶ Instituto de Hipertensão, Belo Horizonte, Minas Gerais, Brazil; Fundação Hospitalar do Estado de Minas Gerais (FHEMIG), Belo Horizonte, Minas Gerais, Brazil.; Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
⁷ Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address: karinabgb@ufmg.br.

PMID: 37852542
DOI: 10.1016/j.ijcard.2023.131435

Abstract

Doxorubicin (DOXO)-cardiotoxicity is a limiting factor for breast cancer chemotherapy. The relationship between microparticles (MPs) and cardiotoxicity remains unclear. MPs can be released under varying pathophysiological conditions. Thereby, this study aimed to assess MPs derived from cardiomyocytes (CardioMPs), platelets (PMPs) and those that expresses tissue factor (TFMPs) in 80 women with breast cancer undergoing DOXO-based chemotherapy, with or without cardiotoxicity in a one-year follow-up. We observed in the cardiotoxicity group higher count of total-MPs at T0 (prior chemotherapy) (p = 0.034), CardioMPs at T0 and T1 (just after chemotherapy) (p = 0.009 and p = 0.0034) and TFMPs at T0 (p = 0.011) compared to non-cardiotoxicity group. The results suggest that MPs could be associated to cardiotoxicity due to DOXO treatment in breast cancer patients.

Keywords: Breast cancer; Cardiotoxicity; Doxorubicin; Microparticles.

MeSH terms

Breast Neoplasms* / complications
Breast Neoplasms* / drug therapy
Cardiotoxicity* / etiology
Doxorubicin / adverse effects
Female
Humans
Myocytes, Cardiac
Thromboplastin

Substances

Doxorubicin
Thromboplastin